Symbio Pharmaceuticals Reports Monthly Exercise Status of Warrants

TOKYO, Aug 03 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) reported the monthly exercise status of its warrants for July 2026. The company issued the fifth series of CVI Investments, Inc.-allocated warrants in June 2022 and the sixth series allocated to EVO FUND in August 2025.

For the sixth series of warrants, 0 shares were delivered during July, with 0 warrants exercised. The total number of outstanding warrants was 200,000. The exercise ratio relative to the total issuance was 0%. As of the end of July, there were 120,510 unexercised warrants remaining. Additionally, the seventh series of warrants issued to EVO FUND in August 2025 had their exercise price adjusted but remain non-exercisable until August 2027 due to contractual restrictions.

For the fifth series of warrants, no shares were delivered or warrants exercised in July. The total number of outstanding warrants was 20,000, with an exercise ratio of 19.0% relative to the total issuance. At the end of July, there were 20,000 unexercised warrants remaining. The company adhered to the exercise limitations outlined in the listing regulations, maintaining compliance with the stipulated ratios. Detailed information on these warrants can be found in previous disclosures dated May 16, 2022, and July 22, 2025.